Medrad annual revenues up 9%

Article

Medrad last week announced financial results for its fiscal 1995 (end-January) that saw revenues increase9% and net earnings up as well. The Pittsburgh-based company recordedrevenues for the fiscal year of $78.3 million, compared to $71.7million in the

Medrad last week announced financial results for its fiscal 1995 (end-January) that saw revenues increase9% and net earnings up as well. The Pittsburgh-based company recordedrevenues for the fiscal year of $78.3 million, compared to $71.7million in the prior year. Net earnings in 1995 will be approximately$1.15 per share, compared to 92¢ per share for the same perioda year ago.

Medrad also announced that it has created separate businessunits for its two major businesses, vascular injection systemsand MRI surface coil products. Each unit will have its own dedicatedmanagement team and new product development functions, the companyreported.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.